Good news for people suffering from obesity: America has approved a weight loss drug, which can soon be launched in India also. This medicine is specially designed for patients who suffer from breathing problems during sleep, called obstructive sleep apnea (OSA). The US Food and Drug Administration (FDA) has approved it as an anti-diabetes drug for the first time, and it Zapbound (Tirzeptide) Will be known as. This medication has been approved to control obesity-related OSA in adults.
Currently, moderate to severe OSA is treated through assisted breathing devices such as CPAP and Bi-PAP. alloy lilywhich is building the Zapbound, said that if all approvals are received, they will launch it by 2025. monjaro Will launch in injectable form in India under the brand name. However, the price of the medicine has not been determined yet.
“Our pricing strategy will be tailored keeping in mind the effectiveness of the drug in India and its importance in reducing the health and economic burden associated with type 2 diabetes as well as obesity,” Eloy Lilly said.
According to a study, about 10.4 crore people in India suffer from OSA, out of which 4.7 crore people are facing moderate or severe OSA. OSA occurs when a blockage occurs in a person’s upper airway, preventing breathing during sleep.
The approval of Zapbound for moderate to severe OSA in obese adults is based on two randomized, double-blind, placebo-controlled studies that included 469 adults.
